Arnaud Monier1, Boris Guiu1,2, Rafael Duran1, Serge Aho3, Pierre Bize1, Pierre Deltenre4, Vincent Dunet1, Alban Denys5. 1. Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, 1011, 46 rue du Bugnon, Switzerland. 2. Department of Diagnostic and Interventional Radiology, Montpellier University Hospital, Montpellier, 34000, Avenue Emile Bertin Sans, France. 3. Department of Epidemiology, University Hospital, Dijon, 21000, boulevard Jeanne d'Arc, France. 4. Department of Gastroenterology, Lausanne University Hospital, Lausanne, 1011, 46 rue du Bugnon, Switzerland. 5. Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, 1011, 46 rue du Bugnon, Switzerland. alban.denys@chuv.ch.
Abstract
OBJECTIVES: To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with intermediate-stage hepatocellular carcinoma. METHODS: In this retrospective study, 151 consecutive patients undergoing cTACE or DEB-TACE and MRI 3-6 weeks before and after therapy were included. Toxicity was assessed on imaging (global hepatic damages (GHD), overall biliary injuries, biliary cast, bile duct dilatation, intrahepatic biloma, portal thrombosis), and clinico-biological follow-ups. Tumour response, time to progression (TTP), and overall survival were assessed. Factors influencing complication rate were identified by generalized equation logistic regression model. RESULTS: Biliary injuries and intrahepatic biloma incidence were significantly higher following DEB-TACE (p < 0.001). DEB-TACE showed a significant increased risk of GHD (OR: 3.13 [1.74-5.63], p < 0.001) and biliary injuries (OR: 4.53 [2.37-8.67], p < 0.001). A significant relationship was found between baseline prothrombin value and GHD, biliary injuries and intrahepatic biloma (all p < 0.01), and between the dose of chemotherapy and intrahepatic biloma (p = 0.001). Only TTP was significantly shorter following DEB-TACE compared to cTACE (p = 0.025). CONCLUSIONS: DEB-TACE was associated with increased hepatic toxicities compared to cTACE. GHD, biliary injuries, and intrahepatic biloma were more frequently observed with high baseline prothrombin value, suggesting that cTACE might be more appropriate than DEB-TACE in patients with less advanced cirrhosis. KEY POINTS: • DEB-TACE demonstrated more therapy-related hepatic locoregional complications compared to cTACE. • TACE-related hepatic locoregional toxicities occurred more frequently with high baseline PT value. • cTACE may be more appropriate in patients with high baseline PT value.
OBJECTIVES: To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with intermediate-stage hepatocellular carcinoma. METHODS: In this retrospective study, 151 consecutive patients undergoing cTACE or DEB-TACE and MRI 3-6 weeks before and after therapy were included. Toxicity was assessed on imaging (global hepatic damages (GHD), overall biliary injuries, biliary cast, bile duct dilatation, intrahepatic biloma, portal thrombosis), and clinico-biological follow-ups. Tumour response, time to progression (TTP), and overall survival were assessed. Factors influencing complication rate were identified by generalized equation logistic regression model. RESULTS:Biliary injuries and intrahepatic biloma incidence were significantly higher following DEB-TACE (p < 0.001). DEB-TACE showed a significant increased risk of GHD (OR: 3.13 [1.74-5.63], p < 0.001) and biliary injuries (OR: 4.53 [2.37-8.67], p < 0.001). A significant relationship was found between baseline prothrombin value and GHD, biliary injuries and intrahepatic biloma (all p < 0.01), and between the dose of chemotherapy and intrahepatic biloma (p = 0.001). Only TTP was significantly shorter following DEB-TACE compared to cTACE (p = 0.025). CONCLUSIONS: DEB-TACE was associated with increased hepatic toxicities compared to cTACE. GHD, biliary injuries, and intrahepatic biloma were more frequently observed with high baseline prothrombin value, suggesting that cTACE might be more appropriate than DEB-TACE in patients with less advanced cirrhosis. KEY POINTS: • DEB-TACE demonstrated more therapy-related hepatic locoregional complications compared to cTACE. • TACE-related hepatic locoregional toxicities occurred more frequently with high baseline PT value. • cTACE may be more appropriate in patients with high baseline PT value.
Entities:
Keywords:
Chemoembolization; Hepatocellular carcinoma; Magnetic resonance imaging; TACE; Toxicity
Authors: Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi Journal: Saudi J Gastroenterol Date: 2020-10 Impact factor: 2.485
Authors: L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu Journal: Curr Oncol Date: 2020-11-01 Impact factor: 3.677
Authors: Mariam S Aboian; Jay F Yu; Ayushi Gautam; Chia-Hung Sze; Jeffrey K Yang; Jonathan Chan; Prasheel V Lillaney; Caroline D Jordan; Hee-Jeung Oh; David M Wilson; Anand S Patel; Mark W Wilson; Steven W Hetts Journal: Biomed Microdevices Date: 2016-12 Impact factor: 2.838
Authors: Natally Horvat; Ana I de Oliveira; Brunna Clemente de Oliveira; Jose A B Araujo-Filho; Maria El Homsi; Ahmed Elsakka; Raazi Bajwa; Guilherme L P Martins; Khaled M Elsayes; Marcos R Menezes Journal: Radiographics Date: 2022-10 Impact factor: 6.312